Publications
Detailed Information
Mycobacterium abscessus pulmonary disease: Individual patient data meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwak, Nakwon | - |
dc.contributor.author | Dalcolmo, Margareth Pretti | - |
dc.contributor.author | Daley, Charles L. | - |
dc.contributor.author | Eather, Geoffrey | - |
dc.contributor.author | Gayoso, Regina | - |
dc.contributor.author | Hasegawa, Naoki | - |
dc.contributor.author | Jhun, Byung Woo | - |
dc.contributor.author | Koh, Won-Jung | - |
dc.contributor.author | Namkoong, Ho | - |
dc.contributor.author | Park, Jimyung | - |
dc.contributor.author | Thomson, Rachel | - |
dc.contributor.author | van Ingen, Jakko | - |
dc.contributor.author | Zweijpfenning, Sanne M. H. | - |
dc.contributor.author | Yim, Jae-Joon | - |
dc.date.accessioned | 2024-08-08T01:28:52Z | - |
dc.date.available | 2024-08-08T01:28:52Z | - |
dc.date.created | 2020-04-09 | - |
dc.date.created | 2020-04-09 | - |
dc.date.issued | 2019-07 | - |
dc.identifier.citation | European Respiratory Journal, Vol.54 No.1 | - |
dc.identifier.issn | 0903-1936 | - |
dc.identifier.uri | https://hdl.handle.net/10371/206188 | - |
dc.description.abstract | Treatment of Mycobacterium abscessus pulmonary disease (MAB-PD), caused by M. abscessus subsp. abscessus, M. abscessus subsp. massiliense or M. abscessus subsp. bolletii, is challenging. We conducted an individual patient data meta-analysis based on studies reporting treatment outcomes for MAB-PD to clarify treatment outcomes for MAB-PD and the impact of each drug on treatment outcomes. Treatment success was defined as culture conversion for. 12 months while on treatment or sustained culture conversion without relapse until the end of treatment. Among 14 eligible studies, datasets from eight studies were provided and a total of 303 patients with MAB-PD were included in the analysis. The treatment success rate across all patients with MAB-PD was 45.6%. The specific treatment success rates were 33.0% for M. abscessus subsp. abscessus and 56.7% for M. abscessus subsp. massiliense. For MAB-PD overall, the use of imipenem was associated with treatment success (adjusted odds ratio (aOR) 2.65, 95% CI 1.36-5.10). For patients with M. abscessus subsp. abscessus, the use of azithromycin (aOR 3.29, 95% CI 1.26-8.62), parenteral amikacin (aOR 1.44, 95% CI 1.05-1.99) or imipenem (aOR 7.96, 95% CI 1.52-41.6) was related to treatment success. For patients with M. abscessus subsp. massiliense, the choice among these drugs was not associated with treatment outcomes. Treatment outcomes for MAB-PD are unsatisfactory. The use of azithromycin, amikacin or imipenem was associated with better outcomes for patients with M. abscessus subsp. abscessus. | - |
dc.language | 영어 | - |
dc.publisher | European Respiratory Society | - |
dc.title | Mycobacterium abscessus pulmonary disease: Individual patient data meta-analysis | - |
dc.type | Article | - |
dc.identifier.doi | 10.1183/13993003.01991-2018 | - |
dc.citation.journaltitle | European Respiratory Journal | - |
dc.identifier.wosid | 000486537500027 | - |
dc.identifier.scopusid | 2-s2.0-85068745713 | - |
dc.citation.number | 1 | - |
dc.citation.volume | 54 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Yim, Jae-Joon | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | LUNG-DISEASE | - |
dc.subject.keywordPlus | TREATMENT OUTCOMES | - |
dc.subject.keywordPlus | ANTIMICROBIAL SUSCEPTIBILITY | - |
dc.subject.keywordPlus | NONTUBERCULOUS MYCOBACTERIA | - |
dc.subject.keywordPlus | PARTICIPANT DATA | - |
dc.subject.keywordPlus | MASSILIENSE | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | CLOFAZIMINE | - |
dc.subject.keywordPlus | PREVALENCE | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.